Literature DB >> 21312407

Neurocognition in schizophrenia.

Solomon Kalkstein1, Irene Hurford, Ruben C Gur.   

Abstract

Neuropsychological deficits among schizophrenia patients have been consistently documented in research over the past 20 years and are reviewed in this chapter. Discussion of general abilities is presented as a background and is followed by analysis of functioning in specific cognitive domains. Overall intellectual deficits are indicated by results from both general intelligence tests and composite test battery scores. Within specific cognitive domains, effect size differences are noted in numerous areas, including attention, with indications that working memory is affected more severely than simple attention, likely due to inclusion of an executive component in such tasks. There is also evidence of slowed processing speed among schizophrenia patients, likely contributing to deficits in other domains which rely on rapid and efficient assimilation of information. Executive impairments have been found on tests assessing set-shifting abilities, selective attention, and inhibition of inappropriate responses. Learning and memory deficits have been demonstrated extensively, with some evidence that recall of verbal material is more affected than recall of visual information, and that recognition abilities are comparatively less impaired than recall for both modalities. Receptive and expressive language abilities are compromised in schizophrenia patients, as well as visual perceptual, constructional, and fine motor skills. Social cognition is an area of particular importance due to its relevance to functional outcome. Deficits in expression and recognition of facial and prosodic affect have been demonstrated, although subjective experience of emotion appears to be relatively well preserved. Neuropsychological deficits described in this review appear to generally remain stable throughout adulthood, supporting neurodevelopmental, rather than neurodegenerative, models of the illness. Finally, cognitive deficits are increasingly used as endophenotypes, which is likely an important direction of future research.

Entities:  

Mesh:

Year:  2010        PMID: 21312407     DOI: 10.1007/7854_2010_42

Source DB:  PubMed          Journal:  Curr Top Behav Neurosci        ISSN: 1866-3370


  53 in total

Review 1.  Predicting the risk of psychosis onset: advances and prospects.

Authors:  Eric V Strobl; Shaun M Eack; Vaidy Swaminathan; Shyam Visweswaran
Journal:  Early Interv Psychiatry       Date:  2012-07-08       Impact factor: 2.732

2.  Evidence of systematic attenuation in the measurement of cognitive deficits in schizophrenia.

Authors:  Michael L Thomas; Virginie M Patt; Andrew Bismark; Joyce Sprock; Melissa Tarasenko; Gregory A Light; Gregory G Brown
Journal:  J Abnorm Psychol       Date:  2017-03-09

3.  Impaired white matter connectivity between regions containing mirror neurons, and relationship to negative symptoms and social cognition, in patients with first-episode schizophrenia.

Authors:  Yukiko Saito; Marek Kubicki; Inga Koerte; Tatsui Otsuka; Yogesh Rathi; Ofer Pasternak; Sylvain Bouix; Ryan Eckbo; Zora Kikinis; Christian Clemm von Hohenberg; Tomohide Roppongi; Elisabetta Del Re; Takeshi Asami; Sang-Hyuk Lee; Sarina Karmacharya; Raquelle I Mesholam-Gately; Larry J Seidman; James Levitt; Robert W McCarley; Martha E Shenton; Margaret A Niznikiewicz
Journal:  Brain Imaging Behav       Date:  2018-02       Impact factor: 3.978

4.  Compromised small-world efficiency of structural brain networks in schizophrenic patients and their unaffected parents.

Authors:  Hao Yan; Lin Tian; Qifeng Wang; Qiang Zhao; Weihua Yue; Jun Yan; Bing Liu; Dai Zhang
Journal:  Neurosci Bull       Date:  2015-03-27       Impact factor: 5.203

5.  Sleep correlates of cognition in early course psychotic disorders.

Authors:  Matcheri S Keshavan; Debra M Montrose; Jean M Miewald; Ripu D Jindal
Journal:  Schizophr Res       Date:  2011-07-02       Impact factor: 4.939

6.  Neonatal exposure to phenobarbital potentiates schizophrenia-like behavioral outcomes in the rat.

Authors:  S K Bhardwaj; P A Forcelli; G Palchik; K Gale; L K Srivastava; A Kondratyev
Journal:  Neuropharmacology       Date:  2012-02-15       Impact factor: 5.250

Review 7.  Different Paths to Core Pathology: The Equifinal Model of the Schizophrenia Syndrome.

Authors:  Isobel W Green; Jill R Glausier
Journal:  Schizophr Bull       Date:  2015-09-20       Impact factor: 9.306

8.  Pharmacogenetic associations of the type-3 metabotropic glutamate receptor (GRM3) gene with working memory and clinical symptom response to antipsychotics in first-episode schizophrenia.

Authors:  Jeffrey R Bishop; James L Reilly; Margret S H Harris; Shitalben R Patel; Rick Kittles; Judith A Badner; Konasale M Prasad; Vishwajit L Nimgaonkar; Matcheri S Keshavan; John A Sweeney
Journal:  Psychopharmacology (Berl)       Date:  2014-08-07       Impact factor: 4.530

9.  Altered prefrontal activity and connectivity predict different cognitive deficits in schizophrenia.

Authors:  Fabio Ferrarelli; Brady A Riedner; Michael J Peterson; Giulio Tononi
Journal:  Hum Brain Mapp       Date:  2015-08-19       Impact factor: 5.038

10.  An examination of associations between the inability to taste phenylthiocarbamide (PTC) and clinical characteristics and trait markers in first-episode, nonaffective psychotic disorders.

Authors:  Michael T Compton; Dawn F Ionescu; Beth Broussard; Sarah L Cristofaro; Stephanie Johnson; Patrick J Haggard; Amy A Potts; Claire Ramsay Wan; Elaine F Walker
Journal:  Psychiatry Res       Date:  2013-04-16       Impact factor: 3.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.